Chemomab Therapeutics (CMMB) Other Non-Current Assets (2017 - 2025)
Chemomab Therapeutics posted quarterly Other Non-Current Assets of $211000.0 for Q4 2025, down 45.19% year-on-year from $385000.0 in Q4 2024, and down 16.93% on a QoQ basis from $254000.0 in Q3 2025.
Chemomab Therapeutics (CMMB) has 9 years of Other Non-Current Assets data on file, last reported at $211000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Assets fell 45.19% year-over-year to $211000.0; the trailing twelve-month figure through Dec 2025 stood at $211000.0 (down 45.19% YoY), and the FY2025 full-year result was $211000.0, down 45.19% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $211000.0, down from $254000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $908000.0 in Q4 2021 and bottomed at $51000.0 in Q1 2021.
- The 5-year median for Other Non-Current Assets is $406500.0 (2024), against an average of $409200.0.
- The widest annual swing landed in 2021, when Other Non-Current Assets soared 22600.0%; it then plunged 45.19% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $908000.0 in 2021, then fell by 19.27% to $733000.0 in 2022, then decreased by 23.74% to $559000.0 in 2023, then plunged by 31.13% to $385000.0 in 2024, then sank by 45.19% to $211000.0 in 2025.
- The last three Other Non-Current Assets figures came in at $211000.0 (Q4 2025), $254000.0 (Q3 2025), and $298000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | 211,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 211,000.00 |
| Sep 30, 2025 | 254,000.00 |
| Jun 30, 2025 | 298,000.00 |
| Mar 31, 2025 | 341,000.00 |
| Dec 31, 2024 | 385,000.00 |
| Sep 30, 2024 | 428,000.00 |
| Jun 30, 2024 | 472,000.00 |
| Mar 31, 2024 | 516,000.00 |
| Dec 31, 2023 | 559,000.00 |
| Sep 30, 2023 | 603,000.00 |
| Jun 30, 2023 | 646,000.00 |
| Mar 31, 2023 | 690,000.00 |
| Dec 31, 2022 | 733,000.00 |
| Sep 30, 2022 | 77,000.00 |
| Jun 30, 2022 | 821,000.00 |
| Mar 31, 2022 | 85,000.00 |
| Dec 31, 2021 | 908,000.00 |
| Sep 30, 2021 | 53,000.00 |
| Jun 30, 2021 | 53,000.00 |
| Mar 31, 2021 | 51,000.00 |
| Dec 31, 2020 | 4,000.00 |
| Sep 30, 2020 | 52,000.00 |
| Jun 30, 2020 | 51,000.00 |
| Mar 31, 2020 | 46,000.00 |
| Dec 31, 2019 | 130,000.00 |
| Sep 30, 2019 | 958,000.00 |
| Jun 30, 2019 | 1.03 Mn |
| Dec 31, 2018 | 1.12 Mn |
| Dec 31, 2017 | 11,000.00 |